{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:16Z","timestamp":1781649916859,"version":"3.54.5"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40620-017-0402-1","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T11:36:16Z","timestamp":1493811376000},"page":"37-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-3089","authenticated-orcid":false,"given":"Mirco","family":"Belingheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"issue":"2","key":"402_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/snep.2003.50025","volume":"23","author":"C Kitiyakara","year":"2003","unstructured":"Kitiyakara C, Kopp JB, Eggers P (2003) Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol 23(2):172\u2013182. doi: 10.1053\/snep.2003.50025","journal-title":"Semin Nephrol"},{"issue":"11","key":"402_CR2","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1681\/ASN.2012040389","volume":"23","author":"SM Korbet","year":"2012","unstructured":"Korbet SM (2012) Treatment of primary FSGS in adults. J Am Soc Nephrol 23(11):1769\u20131776. doi: 10.1681\/ASN.2012040389","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"402_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1681\/ASN.2004070593","volume":"16","author":"S Troyanov","year":"2005","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 16(4): 1061\u20131068. doi: 10.1681\/ASN.2004070593","journal-title":"J Am Soc Nephrol"},{"key":"402_CR4","doi-asserted-by":"publisher","unstructured":"Collins AJ, Foley RN, Herzog C et al (2013) US renal data system 2012 annual data report. Am J Kidney Dis 61(1 Suppl 1):A7, e1\u2013476. doi: 10.1053\/j.ajkd.2012.11.031","DOI":"10.1053\/j.ajkd.2012.11.031"},{"issue":"3","key":"402_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2215\/CJN.04121206","volume":"2","author":"L Barisoni","year":"2007","unstructured":"Barisoni L, Schnaper HW, Kopp JB (2007) A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2(3):529\u2013542. doi: 10.2215\/CJN.04121206","journal-title":"Clin J Am Soc Nephrol"},{"key":"402_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4632768","author":"B Sprangers","year":"2016","unstructured":"Sprangers B, Meijers B, Appel G (2016) FSGS: diagnosis and diagnostic work-up. Biomed Res Int. doi: 10.1155\/2016\/4632768","journal-title":"Biomed Res Int"},{"issue":"25","key":"402_CR7","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1056\/NEJMra1106556","volume":"365","author":"VD D\u2019Agati","year":"2011","unstructured":"D\u2019Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. N Engl J Med 365(25):2398\u20132411. doi: 10.1056\/NEJMra1106556","journal-title":"N Engl J Med"},{"key":"402_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9643785","author":"A Kronbichler","year":"2016","unstructured":"Kronbichler A, Oh J, Meijers B, Shin JI (2016) Focal segmental glomerulosclerosis: genetics, mechanism, and therapies. Biomed Res Int. doi: 10.1155\/2016\/9643785","journal-title":"Biomed Res Int"},{"issue":"3","key":"402_CR9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1681\/ASN.V103552","volume":"10","author":"M Sharma","year":"1999","unstructured":"Sharma M, Sharma R, McCarthy ET, Savin VJ (1999) \u201cThe FSGS factor:\u201d enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 10(3):552\u2013561","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"402_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1681\/ASN.2014090916","volume":"27","author":"M Schwartzman","year":"2016","unstructured":"Schwartzman M, Reginensi A, Wong JS, Basgen JM, Meliambro K, Nicholas SB, D\u2019Agati V, McNeill H, Campbell KN (2016) Podocyte-specific deletion of yes-associated protein causes fsgs and progressive renal failure. J Am Soc Nephrol 27(1):216\u2013226. doi: 10.1681\/ASN.2014090916","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"402_CR11","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2215\/CJN.10571011","volume":"7","author":"H Fatima","year":"2012","unstructured":"Fatima H, Moeller MJ, Smeets B, Yang HC, D\u2019Agati VD, Alpers CE, Fogo AB (2012) Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 7(11):1852\u20131858. doi: 10.2215\/CJN.10571011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"402_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines application to the individual patient. Kidney Int 82(8):840\u2013856. doi: 10.1038\/ki.2012.280","journal-title":"Kidney Int"},{"issue":"6","key":"402_CR13","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","volume":"70","author":"CY Xing","year":"2006","unstructured":"Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW (2006) Direct effects of dexamethasone on human podocytes. Kidney Int 70(6):1038\u20131045. doi: 10.1038\/sj.ki.5001655","journal-title":"Kidney Int"},{"issue":"3","key":"402_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1096\/fj.01-0681com","volume":"16","author":"WE Smoyer","year":"2002","unstructured":"Smoyer WE, Ransom RF (2002) Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction. FASEB J 16(3):315\u2013326. doi: 10.1096\/fj.01-0681com","journal-title":"FASEB J"},{"issue":"8","key":"402_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.2008111219","volume":"20","author":"S Hussain","year":"2009","unstructured":"Hussain S, Romio L, Saleem M, Mathieson P, Serrano M, Moscat J, Diaz-Meco M, Scambler P, Koziell A (2009) Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol 20(8):1733\u20131743. doi: 10.1681\/ASN.2008111219","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"402_CR16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","volume":"25","author":"JJ Rydel","year":"1995","unstructured":"Rydel JJ, Korbet SM, Borok RZ, Schwartz MM (1995) Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 25(4):534\u2013542","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"402_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/ndt\/gfr430","volume":"27","author":"N Jafry","year":"2012","unstructured":"Jafry N, Ahmed E, Mubarak M, Kazi J, Akhter F (2012) Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant 27(3):1101\u20131106. doi: 10.1093\/ndt\/gfr430","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"402_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","volume":"15","author":"MJ Chun","year":"2004","unstructured":"Chun MJ, Korbet SM, Schwartz MM, Lewis EJ (2004) Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15(8):2169\u20132177. doi: 10.1097\/01.ASN.0000135051.62500.97","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"402_CR19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","volume":"32","author":"DC Cattran","year":"1998","unstructured":"Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32(1):72\u201379","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"402_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG.(2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken)62(11):1515\u20131526. doi: 10.1002\/acr.20295","journal-title":"Arthritis Care Res"},{"issue":"6","key":"402_CR21","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D\u2019Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12(6):1164\u20131172","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"402_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1586\/eci.12.109","volume":"9","author":"C Ponticelli","year":"2013","unstructured":"Ponticelli C, Graziani G (2013) Current and emerging treatments for idiopathic focal and segmental glomerulosclerosis in adults. Expert Rev Clin Immunol 9(3):251\u2013261. doi: 10.1586\/eci.12.109","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"402_CR23","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","volume":"56","author":"DC Cattran","year":"1999","unstructured":"Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56(6):2220\u20132226. doi: 10.1046\/j.1523-1755.1999.00778.x","journal-title":"Kidney Int"},{"issue":"1","key":"402_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/ndt\/gfq617","volume":"26","author":"E Sch\u00f6nenberger","year":"2011","unstructured":"Sch\u00f6nenberger E, Ehrich JH, Haller H, Schiffer M (2011) The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 26(1):18\u201324. doi: 10.1093\/ndt\/gfq617","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"402_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14(9):931\u2013938. doi: 10.1038\/nm.1857","journal-title":"Nat Med"},{"key":"402_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4192578","author":"A Beer","year":"2016","unstructured":"Beer A, Mayer G, Kronbichler A (2016) Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int. doi: 10.1155\/2016\/4192578","journal-title":"Biomed Res Int"},{"issue":"5","key":"402_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/ncb1400","volume":"8","author":"K Asanuma","year":"2006","unstructured":"Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P (2006) Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8(5):485\u2013491. doi: 10.1038\/ncb1400","journal-title":"Nat Cell Biol"},{"issue":"6","key":"402_CR28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","volume":"43","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C, Rizzoni G, Edefonti A et al (1993) A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43(6):1377\u20131384","journal-title":"Kidney Int"},{"issue":"8","key":"402_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson DS, Trachtman H, Kaskel FJ et al (2011) Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 80(8):868\u2013878. doi: 10.1038\/ki.2011.195","journal-title":"Kidney Int"},{"issue":"3","key":"402_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2215\/CJN.07110615","volume":"11","author":"LP Laurin","year":"2016","unstructured":"Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH (2016) Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS. Clin J Am Soc Nephrol 11(3):386\u2013394. doi: 10.2215\/CJN.07110615","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"402_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3265\/Nefrologia.pre2011.Feb.10870","volume":"31","author":"A Segarra Medrano","year":"2011","unstructured":"Segarra Medrano A, Vila Presas J, Pou Clav\u00e9 L, Maj\u00f3 Masferrer J, Camps Dom\u00e9nech J (2011) Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis. Nefrologia 31(3):286\u2013291. doi: 10.3265\/Nefrologia.pre2011.Feb.10870","journal-title":"Nefrologia"},{"key":"402_CR32","doi-asserted-by":"crossref","unstructured":"Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974; 24; 2 (7878): 423\u2013427.","DOI":"10.1016\/S0140-6736(74)91814-5"},{"issue":"1","key":"402_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000346256","volume":"37","author":"H Ren","year":"2013","unstructured":"Ren H, Shen P, Li X, Pan X, Zhang W, Chen N (2013) Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol 37(1):84\u201390. doi: 10.1159\/000346256","journal-title":"Am J Nephrol"},{"issue":"1","key":"402_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2009.02.018","volume":"54","author":"X Li","year":"2009","unstructured":"Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J (2009) Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 54(1):51\u201358. doi: 10.1053\/j.ajkd.2009.02.018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"402_CR35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","volume":"10","author":"GA Leget","year":"1998","unstructured":"Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 10(6):548\u2013551.","journal-title":"Curr Opin Oncol"},{"key":"402_CR36","doi-asserted-by":"publisher","unstructured":"Fornoni A, Sageshima J, Wei C et al. (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 3(85). doi: 10.1126\/scitranslmed.3002231","DOI":"10.1126\/scitranslmed.3002231"},{"issue":"7","key":"402_CR37","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794\u2013797. doi: 10.1007\/s00467-004-1434-z","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"402_CR38","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","volume":"21","author":"RD Gilbert","year":"2006","unstructured":"Gilbert RD, Hulse E, Rigden S (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21(11):1698\u20131700. doi: 10.1007\/s00467-006-0228-x","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"402_CR39","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C et al (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84(5):1025\u20131033. doi: 10.1038\/ki.2013.211","journal-title":"Kidney Int"},{"issue":"8","key":"402_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2215\/CJN.00570109","volume":"4","author":"G Fernandez-Fresnedo","year":"2009","unstructured":"Fernandez-Fresnedo G, Segarra A, Gonz\u00e1lez E, Alexandru S, Delgado R, Ramos N, Egido J, Praga M; Trabajo de Enfermedades Glomerulares de la Sociedad Espa\u00f1ola de Nefrolog\u00eda (GLOSEN) (2009) Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 4(8):1317\u20131323. doi: 10.2215\/CJN.00570109 .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"402_CR41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23(6):1117\u20131124. doi: 10.1681\/ASN.2011080775","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"402_CR42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000183469","volume":"40","author":"SW Zimmerman","year":"1985","unstructured":"Zimmerman SW (1985) Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis. Nephron 40(2):241\u2013245","journal-title":"Nephron"},{"issue":"3","key":"402_CR43","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jca.21221","volume":"27","author":"WF Clark","year":"2012","unstructured":"Clark WF (2012) Plasma exchange for renal disease: evidence and use 2011. J Clin Apher 27(3):112\u2013116. doi: 10.1002\/jca.21221","journal-title":"J Clin Apher"},{"issue":"6","key":"402_CR44","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1093\/ndt\/13.6.1524","volume":"13","author":"AH Mitwalli","year":"1998","unstructured":"Mitwalli AH (1998) Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 13(6):1524\u20131528","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"402_CR45","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/ndt\/14.11.2650","volume":"14","author":"MB Andresdottir","year":"1999","unstructured":"Andresdottir MB, Ajubi N, Croockewit S, Assmann KJ, Hibrands LB, Wetzels JF (1999) Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. Nephrol Dial Transplant 14(11):2650\u20132656","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"402_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/gfp538","volume":"25","author":"C Ponticelli","year":"2010","unstructured":"Ponticelli C (2010) Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 25(1):25\u201331. doi: 10.1093\/ndt\/gfp538","journal-title":"Nephrol Dial Transplant"},{"key":"402_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0322-7","author":"A Kashgary","year":"2016","unstructured":"Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, Clark WF.(2016) The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 17(1): doi: 10.1186\/s12882-016-0322-7","journal-title":"BMC Nephrol"},{"issue":"7","key":"402_CR48","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","volume":"45","author":"MC Villarroel","year":"2009","unstructured":"Villarroel MC, Hidalgo M, Jimeno A (2009) Mycophenolate mofetil: an update. Dru gs Today (Barc). 45(7): 521\u2013532. doi: 10.1358\/dot.2009.45.7.1384878","journal-title":"Dru gs Today (Barc)"},{"issue":"6","key":"402_CR49","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","volume":"23","author":"L Senthil Nayagam","year":"2008","unstructured":"Senthil Nayagam L, Ganguli A, Rathi M, Kohli HS, Gupta KL, Joshi K, Sakhuja V, Jha V (2008) Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 23(6):1926\u20131930. doi: 10.1093\/ndt\/gfm538","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"402_CR50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1328-8067.2002.01536.x","volume":"44","author":"S Yokota","year":"2002","unstructured":"Yokota S (2002) Mizoribine: mode of action and effects in clinical use. Pediatr Int 44(2):196\u2013198","journal-title":"Pediatr Int"},{"issue":"9","key":"402_CR51","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1681\/ASN.2006070732","volume":"18","author":"A Nakajo","year":"2007","unstructured":"Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, Kurayama R, Sekine Y, Bessho F, Takahashi S, Swiatecka-Urban A, Tryggvason K, Yan K (2007) Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 18(9):2554\u20132564. doi: 10.1681\/ASN.2006070732","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"402_CR52","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00467-011-1876-z","volume":"26","author":"T Aizawa-Yashiro","year":"2011","unstructured":"Aizawa-Yashiro T, Tsuruga K, Watanabe S, Oki E, Ito E, Tanaka H (2011) Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol 26(8):1255\u20131261. doi: 10.1007\/s00467-011-1876-z","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"402_CR53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1620\/tjem.205.87","volume":"205","author":"H Tanaka","year":"2005","unstructured":"Tanaka H, Tsugawa K, Nakahata T, Kudo M, Onuma S, Kimura S, Ito E (2005) Mizoribine pulse therapy for a pediatric patient with steroid-resistant nephrotic syndrome. Tohoku J Exp Med 205(1):87\u201391","journal-title":"Tohoku J Exp Med"},{"issue":"9","key":"402_CR54","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/ndt\/gfp278","volume":"24","author":"E Smet De","year":"2009","unstructured":"De Smet E, Rioux JP, Ammann H, D\u00e9ziel C, Qu\u00e9rin S (2009) FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 24(9):2938\u20132940. doi: 10.1093\/ndt\/gfp278","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"402_CR55","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00467-013-2539-z","volume":"28","author":"K Sgambat","year":"2013","unstructured":"Sgambat K, Banks M, Moudgil A. (2013) Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome. Pediatr Nephrol 28(11): 2131\u20132135. doi: 10.1007\/s00467-013-2539-z","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"402_CR56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1744-9987.2011.00949.x","volume":"15","author":"M Kopa\u010d","year":"2011","unstructured":"Kopa\u010d M, Megli\u010d A, Rus RR (2011) Partial remission of resistant nephrotic syndrome after oral galactose therapy. Ther Apher Dial 15(3):269\u2013272. doi: 10.1111\/j.1744-9987.2011.00949.x","journal-title":"Ther Apher Dial"},{"issue":"6","key":"402_CR57","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1681\/ASN.V361260","volume":"3","author":"VJ Savin","year":"1992","unstructured":"Savin VJ, Sharma R, Lovell HB, Welling DJ (1992) Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3(6):1260\u20131269","journal-title":"J Am Soc Nephrol"},{"key":"402_CR58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","volume":"16","author":"H Trachtman","year":"2015","unstructured":"Trachtman H, Vento S, Herreshoff E et al (2015) Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol 16:111. doi: 10.1186\/s12882-015-0094-5","journal-title":"BMC Nephrol"},{"issue":"10","key":"402_CR59","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser J, von Gersdorff G, Loos M et al (2004) Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 113(10):1390\u20131397","journal-title":"J Clin Invest"},{"issue":"25","key":"402_CR60","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu CC, Fornoni A, Weins A et al (2013) Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369(25):2416\u20132423. doi: 10.1056\/NEJMoa1304572","journal-title":"N Engl J Med"},{"issue":"11","key":"402_CR61","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114\u20131123","journal-title":"N Engl J Med"},{"issue":"8","key":"402_CR62","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1681\/ASN.2015091002","volume":"27","author":"M Delville","year":"2016","unstructured":"Delville M, Baye E, Durrbach A et al (2016) B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS. J Am Soc Nephrol 27(8):2520\u20132527. doi: 10.1681\/ASN.2015091002","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"402_CR63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1152\/ajprenal.00510.2015","volume":"310","author":"R Novelli","year":"2016","unstructured":"Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G (2016) Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? Am J Physiol Renal Physiol 310(5):335\u2013341. doi: 10.1152\/ajprenal.00510.2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"402_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep27589","author":"Y Qiao","year":"2016","unstructured":"Qiao Y, Berg AL, Wang P, Ge Y, Quan S, Zhou S, Wang H, Liu Z, Gong R. (2016) MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci Rep. Epub. doi: 10.1038\/srep27589","journal-title":"Sci Rep"},{"issue":"12","key":"402_CR65","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.2215\/CJN.02840313","volume":"8","author":"J Hogan","year":"2013","unstructured":"Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA (2013) Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol 8(12):2072\u20132081. doi: 10.2215\/CJN.02840313","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"402_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","volume":"69","author":"Y Liu","year":"2006","unstructured":"Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69(2):213\u2013217","journal-title":"Kidney Int"},{"issue":"6","key":"402_CR67","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1111\/j.1523-1755.2004.66038.x","volume":"66","author":"V Vielhauer","year":"2004","unstructured":"Vielhauer V, Berning E, Eis V, Kretzler M, Segerer S, Strutz F, Horuk R, Gr\u00f6ne HJ, Schl\u00f6ndorff D, Anders HJ (2004) CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 66(6):2264\u20132278. doi: 10.1111\/j.1523-1755.2004.66038.x","journal-title":"Kidney Int"},{"issue":"5","key":"402_CR68","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1046\/j.1523-1755.2003.00288.x","volume":"64","author":"JH Kim","year":"2003","unstructured":"Kim JH, Kim BK, Moon KC, Hong HK, Lee HS (2003) Activation of the TGF-beta\/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 64(5):1715\u20131721","journal-title":"Kidney Int"},{"issue":"3","key":"402_CR69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1517\/14712598.7.3.293","volume":"7","author":"E Gagliardini","year":"2007","unstructured":"Gagliardini E, Benigni A (2007) Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther 7(3):293\u2013304. doi: 10.1517\/14712598.7.3.293","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"402_CR70","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0192-0561(98)00042-3","volume":"20","author":"WC Cain","year":"1998","unstructured":"Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS (1998) Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 20(12):685\u2013695","journal-title":"Int J Immunopharmacol"},{"issue":"9","key":"402_CR71","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","volume":"171","author":"A Azuma","year":"2005","unstructured":"Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, Sato A, Kudoh S (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171(9):1040\u20131047","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"402_CR72","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA, Donohue M, Ramachandrarao S, Xu R, Fervenza FC, Kopp JB (2011) Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22(6):1144\u20131151. doi: 10.1681\/ASN.2010101049","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"402_CR73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","volume":"54","author":"T Shimizu","year":"1998","unstructured":"Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K (1998) Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54(1):99\u2013109","journal-title":"Kidney Int"},{"issue":"5","key":"402_CR74","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2215\/CJN.01050207","volume":"2","author":"ME Cho","year":"2007","unstructured":"Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB (2007) Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2(5):906\u2013913. doi: 10.2215\/CJN.01050207","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"402_CR75","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"H Trachtman","year":"2011","unstructured":"Trachtman H, Fervenza FC, Gipson DS et al (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79(11):1236\u20131243. doi: 10.1038\/ki.2011.33","journal-title":"Kidney Int"},{"issue":"2","key":"402_CR76","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1523-1755.2005.67116.x","volume":"67","author":"LY Chan","year":"2005","unstructured":"Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN (2005) Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 67(2):602\u2013612. doi: 10.1111\/j.1523-1755.2005.67116.x","journal-title":"Kidney Int"},{"key":"402_CR77","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/317682","author":"S Yung","year":"2013","unstructured":"Yung S, Cheung KF, Zhang Q, Chan TM (2013) Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol. doi: 10.1155\/2013\/317682","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"402_CR78","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","volume":"43","author":"IL Noronha","year":"1993","unstructured":"Noronha IL, Kr\u00fcger C, Andrassy K, Ritz E, Waldherr R (1993) In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43(3):682\u2013692","journal-title":"Kidney Int"},{"issue":"1","key":"402_CR79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbrc.2015.09.121","volume":"467","author":"T Adachi","year":"2015","unstructured":"Adachi T, Arito M, Suematsu N, Kamijo-Ikemori A, Omoteyama K, Sato T, Kurokawa MS, Okamoto K, Kimura K, Shibagaki Y, Kato T. (2015) Roles of layilin in TNF-\u03b1-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem Biophys Res Commu 467(1): 63\u201369. doi: 10.1016\/j.bbrc.2015.09.121","journal-title":"Biochem Biophys Res Commu"},{"issue":"5","key":"402_CR80","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/156652412800619950","volume":"12","author":"MP Miguel De","year":"2012","unstructured":"De Miguel MP, Fuentes-Juli\u00e1n S, Bl\u00e1zquez-Mart\u00ednez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F (2012) Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 12(5):574\u2013591","journal-title":"Curr Mol Med"},{"issue":"8","key":"402_CR81","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, Hou Y, Zeng X, Gilkeson GS, Sun L (2010) Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69(8):1423\u20131429. doi: 10.1136\/ard.2009.123463","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"402_CR82","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.beha.2011.01.003","volume":"24","author":"O Ringden","year":"2011","unstructured":"Ringden O, Le Blanc K (2011) Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. Best Pract Res Clin Haematol 24(1):65\u201372. doi: 10.1016\/j.beha.2011.01.003","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"402_CR83","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.coi.2010.10.012","volume":"22","author":"A Uccelli","year":"2010","unstructured":"Uccelli A, Prockop DJ (2010) Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 22(6):768\u2013774. doi: 10.1016\/j.coi.2010.10.012","journal-title":"Curr Opin Immunol"},{"key":"402_CR84","doi-asserted-by":"publisher","unstructured":"Belingheri M, Lazzari L, Parazzi V et al Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis. Biologicals. 41(6): 439\u2013445. doi: 10.1016\/j.biologicals.2013.09.004","DOI":"10.1016\/j.biologicals.2013.09.004"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-017-0402-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:57:08Z","timestamp":1777564628000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/31\/1\/37\/8371304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s40620-017-0402-1","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]}}}